Mackaness James H

CFO James H Mackaness sold 90,622 shares for $6,293,177.04 across 11 transactions on 2025-03-27, reducing holdings by 46.3%.

James H Mackaness, Chief Financial Officer of Soleno Therapeutics, executed 11 separate sales totaling 90,622 shares for $6,293,177.04 on March 27, 2025, with prices ranging from $65.97 to $72.64 and a blended average of $69.44. This sale reduced his holdings from 195,798 shares to 105,176 shares, a -46.3% reduction in his stake. The company is trading at $71.45, near its 52-week high of $71.99, and has experienced significant recent momentum (+46.4% over 30 days, +59.0% over 90 days). However, Soleno remains unprofitable with a net loss of $-76,616,000.00 in its most recent fiscal year, despite 138.8% annual revenue growth. Across his five prior sales at SLNO, none were well-timed at the 90-day mark—the stock consistently rose after each sale, with 90-day returns ranging from +16.7% to +24.1%—suggesting a pattern where this CFO's equity dispositions have consistently preceded further appreciation rather than preceding declines.

CFO Mackaness James H sold 13,531 shares ($641,782.70) at $47.43 avg on 2024-08-28/29

CFO James H Mackaness executed 4 separate sales totaling 13,531 shares for $641,782.70 over August 28–29, 2024, at an average price of $47.43 per share. His post-transaction holdings declined to 127,249 shares (-9.6% vs pre-transaction). The timing of this sale—coinciding with the stock near its 52-week high of $52.35 (current price $48.95 is -6.5% from that peak)—and the multi-day sequence occur within the same narrow window as his 5 prior trades at SLNO, all executed between August 5–6, 2024. His cross-ticker track record across 8 prior sells shows a 90-day well-timed rate of 0.00%, indicating a pattern of poor timing across his open-market history. The company remains deeply unprofitable (full-year net income $-21,854,000.00) despite strong annual revenue growth of +138.8%, creating an elevated-uncertainty context for valuation.

CFO James H Mackaness sold 14,983 shares of SLNO for $683,201.59 across 5 transactions on Aug 5–6, 2024.

James H Mackaness, Chief Financial Officer of Soleno Therapeutics, executed 5 separate sales totaling 14,983 shares for $683,201.59 at a blended average price of $45.60 on August 5–6, 2024, reducing his holdings by 9.6% from 155,763 to 140,780 shares. The sales occurred when the stock traded in a tight range near the blended average ($43.64–$46.14), within 16.0% of the 52-week high of $52.35. The company remains unprofitable (net income of $-21,854,000.00 in the latest full fiscal year) despite strong annual revenue growth of +138.8%, and the stock has declined 7.7% over the prior 90 days. His prior trades at SLNO (3 separate sells in December 2023) showed positive returns in both 30-day and 90-day periods, meaning the stock rose after those sales; however, no well-timed pattern is evident in the same-ticker history (0 of 3 prior sells were well-timed at the 90-day mark).